Reports

Drug name	NICE TAs	Comments
Cannabidiol (Epidyolex®)	TA614 - Cannabidiol with clobazam for treating seizures associated with Dravet Syndrome TA615 - Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Capecitabine tablets	TA61 - Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer TA191 - Capecitabine for the treatment of advanced gastric cancer TA263 - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA62 - Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer
Capivasertib (Truqap®)	NICE TA 1063 Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment
Caplacizumab (Cablivi®)	TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Carboplatin injection	TA55 - Guidance on the use of paclitaxel in the treatment of ovarian cancer TA91 - Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Carfilzomib	TA457 - Carfilzomib for previously treated multiple myeloma	For hospital use only
Carfilzomib (Kyprolis®)	TA657 - Carfilzomib for previously treated multiple myeloma TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
Carmustine 7.7mg implants	TA121 - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma TA149 - Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)	For hospital use only
Casirivimab plus imdevimab (Ronapreve®)	TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Cemiplimab	TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports